Targeted Dendrimeric Anticancer Prodrug: A Methotrexate-Folic Acid-Poly(amidoamine) Conjugate and a Novel, Rapid, “One Pot” Synthetic Approach
✍ Scribed by Zhang, Yuehua; Thomas, Thommey P.; Desai, Ankur; Zong, Hong; Leroueil, Pascale R.; Majoros, Istvan J.; Baker, James R.
- Book ID
- 127051557
- Publisher
- American Chemical Society
- Year
- 2010
- Tongue
- English
- Weight
- 724 KB
- Volume
- 21
- Category
- Article
- ISSN
- 1043-1802
No coin nor oath required. For personal study only.
✦ Synopsis
A targeted dendrimeric anticancer prodrug, a conjugate of generation 5 (G5) polyamidoamine (PAMAM) dendrimer, folic acid (FA), and methotrexate (MTX), has been successfully synthesized by using a novel "one pot" approach which is simple, reproducible, and feasible for large-scale synthesis. All dendrimer products have been characterized by (1)H NMR, MALDI-TOF, GPC, and HPLC. With this new method, the ratio of FA versus MTX attached to the dendrimer can be easily tuned to achieve the desired therapeutic effect. A new analytical approach for calculating the numbers of FA and MTX attached to the dendrimer has been established. In vitro studies performed on FA receptor-expressing KB cells show that the new conjugate has a similar affinity and cytotoxic potency to G5-FA-MTX synthesized using the traditional multiple-step approach.
📜 SIMILAR VOLUMES